If you liked this article you might like

Impax Gains 38% On CEO Appointment, Talk of Sale
Can This Pharma Stock Withstand the 'Trump Effect'?
Mylan Hit After Abbott Dumps Shares
Immunomedics, Mylan Lead Biotech Movers